Last updated: March 7, 2026
Case Overview
Pfizer Inc. filed a patent infringement lawsuit against Zydus Pharmaceuticals (USA) Inc., in the District of Delaware, numbered 1:22-cv-00210, on January 25, 2022. The case involves Pfizer asserting infringement of a patent related to its blockbuster drug, Sustiva (efavirenz), used to treat HIV-1 infections. Pfizer claims Zydus's generic efavirenz products violate U.S. Patent No. 9,848,516, which covers specific formulations and methods of manufacturing efavirenz.
Patent Details
- Patent Number: 9,848,516
- Filing Date: August 21, 2014
- Issue Date: December 26, 2017
- Assignee: Pfizer Inc.
- Patent Scope: Covers methods of producing efavirenz with specific impurity profiles and formulations that enhance bioavailability and stability.
Allegations
Pfizer alleges Zydus's generic efavirenz products infringe claims related to:
- The impurity profile of efavirenz.
- The specific process of manufacturing efavirenz formulations.
- The stability and bioavailability enhancements claimed in the patent.
Pfizer sought injunctive relief to prevent Zydus from marketing and selling infringing products prior to patent expiration and damages for past sales.
Legal Proceedings
Claims
- Infringement: Pfizer claims Zydus's generic products infringe the '516 patent claims.
- Validity: Pfizer defends patent validity, asserting the claims are novel and non-obvious based on the prior art.
- Injunction: Pfizer seeks a permanent injunction against Zydus manufacturing, marketing, or selling infringing efavirenz.
Zydus Defense
- Non-infringement: Zydus argues its manufacturing processes and formulations do not violate the patent claims.
- Patent invalidity: Zydus counters that the patent claims are obvious and lack novelty due to prior art references.
- Hatch-Waxman: Zydus filed an abbreviated new drug application (ANDA) seeking approval to market a generic efavirenz product.
Court Procedures
- Pfizer filed a patent infringement complaint under the Hatch-Waxman Act framework.
- Zydus filed an ANDA certification, triggering patent litigation.
- The case involves discovery, claim construction, and potential summary judgment motions.
Industry and Market Context
Pfizer’s patent shields a significant revenue stream from Sustiva, which generated over $600 million in global sales in 2021. The case impacts the regulatory pathway for Zydus’s generic efavirenz, with potential delays or exclusions from the market if Pfizer succeeds.
Litigation Status (As of March 2023)
- Preliminary motions: Both parties filed motions to dismiss and for claim construction.
- Discovery phase: Ongoing, with document exchanges and depositions.
- Trial schedule: Expected to commence in late 2023, pending court rulings.
Implications for the Industry
This case exemplifies ongoing patent enforcement strategies by originator pharmaceutical companies to defend formulations and manufacturing processes, particularly in the HIV therapeutic space. It reflects patent holders’ efforts to extend market exclusivity through litigation against generics.
It also underscores the strategic importance of patent validity and infringement defenses in Hatch-Waxman litigation, where generic companies seek to enter the market, and brand-name manufacturers defend market share.
Key Takeaways
- Pfizer asserts a method-of-manufacturing patent covering efavirenz formulations.
- Zydus challenges both infringement and patent validity.
- The outcome influences the timing of Zydus's entry into the U.S. efavirenz market.
- Litigation highlights the importance of patent specificity in generics disputes.
- The case status as of early 2023 remains procedural, with a future trial likely in late 2023.
FAQs
1. What is the significance of the '516 patent in efavirenz commercialization?
It provides patent protection until at least 2032, preventing generic entry and maintaining Pfizer’s market exclusivity.
2. How does Zydus defend against Pfizer’s patent claims?
Zydus claims its manufacturing process and formulation do not infringe and that the patent claims lack novelty and are obvious over prior art.
3. What role does the Hatch-Waxman Act play in this litigation?
It facilitates patent disputes triggered by ANDA filings, giving patent owners the right to sue for infringement before generic entry.
4. How might the case impact drug pricing?
Successful patent enforcement delays generic entry, maintaining higher drug prices. Conversely, invalidation or non-infringement could enable earlier market access.
5. What are potential outcomes?
Possible resolution includes a court ruling on infringement and validity, settlement, or suppression of Zydus’s product if infringement is upheld.
